Merck and FDA knew of potential suicide risk in taking Propecia

Organisation: Position: Deadline Date: Location:

Newly unsealed court documents and other records show that Merck & Co and US regulators knew about reports of suicidal behaviour in men taking the company’s anti-baldness treatment Propecia when they decided not to warn consumers of those potential risks in a 2011 update of the popular drug’s label.

Reuters reports that internal records from Merck were made public in late January, when a federal magistrate in Brooklyn, New York, granted a 2019 motion to unseal 11 documents filed in years of litigation alleging Propecia caused persistent sexual dysfunction and other harmful side effects.

Since the 2011 decision on the warning, the US Food and Drug Administration (FDA) has received more than 700 reports of suicide and suicidal thoughts among people taking Propecia or generic versions of the drug. Those included at least 100 deaths. Before that, in the first 14 years the drug was on the market, the agency received 34 such reports, including 10 deaths.

European and Canadian regulators, citing similar reports among men taking finasteride, require a warning of suicidal thoughts on the label, though they note that research has not proved that the drug causes such thoughts. Reuters reports that to this day, the US label contains no mention of suicide or suicidal thoughts.

As early as 2009, Merck knew of more than 200 reports of depression, including suicidal thoughts, in men taking Propecia, according to an internal “risk management” assessment from that year. The company decided there were too few reports of serious depression and suicidal behaviour and not enough specifics about those cases to warrant more than “routine” monitoring of safety data.

In 2011, two years after the Merck risk analysis, the FDA was weighing a company request to add “depression” to the drug’s label as a potential risk, with no warnings related to suicide. FDA analysts disagreed about adding a warning related to suicide, according to previously unreported government documents. But the regulator ultimately agreed with Merck’s request on the grounds that the number of suicides was lower than one would expect in this group of patients.

According to Reuters, some medical researchers and patient advocates said Merck and the FDA have left American consumers in the dark about potentially life-threatening dangers associated with finasteride.

Michael Irwig, an endocrinologist and Harvard Medical School faculty member whose own research has found possible links between finasteride and suicidal behaviours, said Merck’s handling of the risk analysis and the FDA’s inaction keep critical information from the public. Merck “definitely should have provided a more complete picture,” Irwig said.

The report quotes Merck as saying that “the scientific evidence does not support a causal link between Propecia and suicide or suicidal ideation and these terms should not be included in the labelling” for the drug. “Merck works continuously with regulators to ensure that potential safety signals are carefully analysed and, if appropriate, included in the label for Propecia.”

The FDA statement said it “continues to monitor post-marketing safety data for Propecia.” Overall, the agency noted that the presence of a report in the FDA database “does not mean the drug caused the adverse event” and medical problems may stem from the “underlying disease being treated, caused by some other drug being taken concurrently, or occurred for other reasons.”

Reuters reports that the FDA declined to comment further about its handling of Propecia and reports related to suicide.

 

Full Reuters report (Restricted access)

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.